Mr. Thomas O'Shaughnessy reports

ONCO-INNOVATIONS SIGNS LOI WITH NANOSOFT POLYMERS TO ADVANCE POLYMER AND DRUG DELIVERY DEVELOPMENT FOR THE ONC010 PROGRAM

Onco-Innovations Ltd. has entered into a non-binding letter of intent with Nanosoft Polymers, a biotechnology-focused polymer company, as an initial step toward negotiating a service agreement related to polymer process development, analytical characterization and drug formulation optimization activities for the company's exclusively licensed PNKP inhibitor technology, ONC010. The LOI is non-binding, and there is no certainty that a service agreement will be entered into.

Nanosoft specializes in the development of functional polymers and co-polymers for drug delivery, diagnostics and therapeutic applications. Nanosoft is led by Dr. Xiaobing Xiong, an experienced polymer scientist with extensive expertise in translational polymer engineering and nanotechnology-enabled drug delivery systems. Dr. Xiong worked under the guidance of Dr. Afsaneh Lavasanifar, a leading nanoparticle scientist at the University of Alberta. Both Dr. Xiong and Dr. Lavasanifar are co-inventors of Onco-Innovations' patented nanodelivery system.

The LOI sets out the parties' intent to negotiate toward definitive documentation for proposed polymer-related development activities, which are expected to include polymer synthesis and process optimization, analytical characterization methodology support, formulation optimization activities, encapsulated API development support, and process transfer planning intended to support potential future GMP manufacturing activities.

"This LOI with Nanosoft represents a solid preliminary step as we continue building the technical framework around ONC010. Polymer engineering and nanoparticle formulation are important components of our development pathway, and the proposed relationship with Nanosoft is intended to support further planning around scalability, reproducibility and regulatory readiness," said Thomas O'Shaughnessy, chief executive officer of Onco-Innovations.

Dr. Islam Mohamed, chief medical officer of Onco-Innovations, added: "The development of nanoparticle-based oncology therapeutics requires careful integration of polymer science, formulation engineering and analytical characterization. Dr. Xiong's prior experience with the company's proprietary nanodelivery system, together with Nanosoft's polymer-focused expertise, provides a strong basis for the proposed relationship contemplated by the LOI as we continue preparing ONC010 for future clinical and regulatory development activities."

The company also announces the appointment of Dave Antony as vice-president of corporate finance. Mr. Antony brings more than 35 years of experience assisting companies with financial planning, financial reporting, corporate governance and public company advisory matters.

Throughout his career, Mr. Antony has worked with Canadian and international companies and organizations across a broad range of sectors, including health and wellness, technology, natural resources, regulated gaming, and loyalty and media marketing. He has served as a director or officer of numerous public and private companies, providing financial and governance oversight during various stages of corporate development.

Mr. Antony's experience also includes capital market and exchange-related advisory work. He has served as chairman of the TSX Venture Exchange advisory committee for Alberta and as a member of the TSX-V national advisory committee. His background in public company governance, financial reporting and corporate finance is expected to support Onco as the company continues to advance its oncology-focused development strategy and engage with capital market stakeholders.

About Onco-Innovations Ltd.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide licence to patented technology that targets solid tumours.

We seek Safe Harbor.